Zelluna ASA Logo

Zelluna ASA

Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 08:00
Regulatory News Service
Zelluna Announces Investor Forum on Science & Strategy to be held on Wednesday …
English 3.6 KB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 1.0 MB
2025-08-20 07:00
Investor Presentation
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 801.4 KB
2025-08-20 07:00
Earnings Release
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General …
English 5.6 KB
2025-08-14 12:00
Report Publication Announcement
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
English 1.7 KB
2025-07-03 12:07
Share Issue/Capital Change
Zelluna ASA - Grant of Share Options under Long-Term Incentive Program
English 3.4 KB
2025-06-25 16:19
Major Shareholding Notification
Disclosure of share transfer from Inven2 AS
English 711 bytes
2025-05-27 13:51
Major Shareholding Notification
Disclosure of Shareholding - Gjelsten Holding AS
English 1.2 KB
2025-05-27 13:38
Share Issue/Capital Change
ZLNA - New registered share capital
English 1.9 KB
2025-05-24 06:37
Share Issue/Capital Change
ZLNA - Issuance of shares through set-off of option exercise fee
English 2.3 KB
2025-05-08 05:00
Investor Presentation
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 1.3 MB
2025-05-08 05:00
Quarterly Report
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 664.4 KB
2025-05-08 05:00
Earnings Release
Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General B…
English 6.5 KB
2025-04-30 06:00
Report Publication Announcement
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
English 1.7 KB
2025-04-29 12:50
Post-Annual General Meeting Information
Zelluna ASA - Annual General Meeting held on April 29, 2025
Norwegian 4.6 MB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.